Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?

Community
Company
News
Contact Us
Sign in

Topics: Gynecologic Cancers • Ovarian Cancer

What is your general philosophy when discontinuing and/or switching chemotherapy in the recurrent setting?

Related Questions

How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?

What toxicities related to mirvetuximab have you seen in your patients and how have you managed them?

In the absence of a cohesive workflow guiding the use of PARPi in ovarian cancer since the 2022 FDA approval withdrawals, what is your general approach to PARPi usage in the front-line and recurrent setting?

Do you test ovarian cancer tumors for targetable biomarkers (e.g., HER2, folate receptor, MMR) at the time of primary diagnosis or at time of recurrence?

Would you hold a PARP inhibitor in the perioperative period for an ileostomy reversal in a patient who has completed primary debulking surgery followed by chemotherapy?

Do you routinely give prophylactic antibiotics/steroids for patients on MEK-inhibitors (e.g., trametinib) to prevent rash/dermatitis?

How do you counsel patients with homologous recombination repair proficient tumors already on niraparib maintenance therapy, prior to the FDA restriction?

Has your preferred adjuvant treatment for IC mucinous ovarian cancer changed in response to the platinum chemotherapy shortage?

In a patient with an HR-proficient stage III high-grade serous ovarian cancer s/p R0 primary debulking surgery for whom you are not considering bevacizumab in addition to chemotherapy, would you consider IP chemotherapy?

What platform do you use for HRD testing of ovarian cancers and why?